Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer

Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer

Abstract Objective To analyze the efficacy and adverse effects of anti‐PD‐1 immune checkpoint inhibitors aimed at nasopharyngeal carcinoma (NPC). Methods During the first stage of the study, using 40 patients with stage III/IVa NPC treated with anti‐PD‐1 immune checkpoint inhibitors in combination w...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shuling Shi, Bingyan Li, Pengcheng Zhou, Linhui Chen, Huizhen Li, Yingyi Wang, Xiaoyu Deng, Qianqian Dang, Jingjing Wu, Boya Zha, Peihong Li, Yingjuan Zheng, Daoke Yang
Format:	Article
Language:	English
Published:	Wiley 2024-07-01
Series:	Cancer Medicine
Subjects:	immune checkpoint inhibitors immune‐related adverse events nasopharyngeal cancer PD‐1
Online Access:	https://doi.org/10.1002/cam4.7359
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immune checkpoint inhibition in NPC: A comprehensive review of PD-L1 overexpression and treatment responses
by: Madhan Krishnan, et al.
Published: (2024-12-01)

Exosomal PD-L1 derived from hypoxia nasopharyngeal carcinoma cell exacerbates CD8+ T cell suppression by promoting PD-L1 upregulation in macrophages
by: Xiaofei Yuan, et al.
Published: (2025-05-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
by: Amjad Zafar, et al.
Published: (2024-11-01)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
by: Jingjing Zhao, et al.
Published: (2023-12-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1
by: Bar Kaufman, et al.
Published: (2025-05-01)

Bibliometric analysis reveals the research hotspots and trends of nasopharyngeal carcinoma immunotherapy
by: Gang Wang, et al.
Published: (2024-12-01)

A novel nanomedicine integrating ferroptosis and photothermal therapy, well-suitable for PD-L1-mediated immune checkpoint blockade
by: Yujun Bao, et al.
Published: (2024-12-01)

PD-1 and LAG-3 were optimal combination of immune checkpoints for predicting poor clinical outcomes of patients with ovarian cancer
by: Yifan Wu, et al.
Published: (2025-08-01)

Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications
by: Erfan Rezazadeh‐Gavgani, et al.
Published: (2025-04-01)

Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis
by: Sheng Chen, et al.
Published: (2025-12-01)

Challenges and advances of immune checkpoint therapy
by: Lingyu Li, et al.
Published: (2024-12-01)

Monitoring Pseudoprogression Using Circulating Small Extracellular Vesicles Expressing PD‐L1 in a Melanoma Patient Treated With Immune Checkpoint Inhibitors
by: Charlée Nardin, et al.
Published: (2025-06-01)

Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis
by: Antonious Hazim, et al.
Published: (2025-05-01)

Production of Antibodies Binding Murine Nuclear PD-L1
by: Valentina Kostenko, et al.
Published: (2024-04-01)

Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors
by: Green Hong, et al.
Published: (2025-04-01)

Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
by: Yan Zhang, et al.
Published: (2019-08-01)

PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1
by: Lvyun Zhu, et al.
Published: (2024-12-01)

Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy
by: Tetsuichi Kansha, et al.
Published: (2025-07-01)

Optimizing Immunotherapy: The Synergy of Immune Checkpoint Inhibitors with Artificial Intelligence in Melanoma Treatment
by: Mohammad Saleem, et al.
Published: (2025-04-01)

Thyroid Dysfunction After Intensity-Modulated Radiotherapy and PD⁃1 Inhibitor Treatment for Locally Advanced Nasopharyngeal Carcinoma
by: Shang K, et al.
Published: (2025-01-01)

Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model
by: Caroline Schoenherr, et al.
Published: (2025-01-01)

Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment
by: Xiaoye Shi, et al.
Published: (2024-12-01)

Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis
by: Yi Huang, et al.
Published: (2024-12-01)

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation
by: Tingting Wu, et al.
Published: (2024-12-01)

Scarring alopecia as an unexpected consequence of immune checkpoint inhibition
by: Nelly Kokikian, BS, et al.
Published: (2025-07-01)

A new signature associated with anoikis predicts the outcome and immune infiltration in nasopharyngeal carcinoma
by: Yonglin Luo, et al.
Published: (2025-02-01)

Short-course PD-1 blockade in locally advanced nasopharyngeal carcinoma: a phase II randomized trial protocol (Tori-013)
by: Hongyuan Jia, et al.
Published: (2025-08-01)

Galectin-9 and Tim-3 in gastric cancer: a checkpoint axis driving T cell exhaustion and Treg-mediated immunosuppression independently of anti-PD-1 blockade
by: Charlotte N. Hill, et al.
Published: (2025-07-01)

Evaluating the influence of anti-PD-1 immunotherapy combined with IMRT on thyroid dysfunction in nasopharyngeal carcinoma
by: Liqianqi Chen, et al.
Published: (2025-01-01)

Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity
by: Yoichiro Narikawa, et al.
Published: (2025-08-01)

Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response
by: Assia Hijazi, et al.
Published: (2023-12-01)

PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib
by: Yingfang Feng, et al.
Published: (2025-07-01)

Immunohistochemical Profiling of Immune Checkpoints in Chronic Hepatitis B Liver Tissue
by: João Panão-Costa, et al.
Published: (2025-06-01)

The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study
by: Baoyue Pan, et al.
Published: (2025-06-01)

Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients
by: Yirui Zhai, et al.
Published: (2025-08-01)

Advances in immune checkpoint inhibitor therapy for breast cancer: research progress and future directions
by: ZENG Cheng, WANG Yuanyi, WANG Jiani, MA Fei
Published: (2025-02-01)

Prognostic Significance of Circulating Immune Subset Counts in Nasopharyngeal Carcinoma
by: Xie H, et al.
Published: (2025-06-01)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
by: Lavinia Spain, et al.
Published: (2019-06-01)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01)